Close Sidebar
Nordic Life Science
Now Reading
Immunovia Inc achieves Clinical Laboratory Licensure
Search for content, post, videos
Search for content, post, videos
Advertisement

Immunovia Inc achieves Clinical Laboratory Licensure

May 18, 2022
1055 Views
Jeff Borcherding

The Rhode Island Department of Health has granted Immunovia, Inc., the US subsidiary of Immunovia, Clinical Laboratory licensure.

The licensure allows physicians in Rhode Island to order the IMMray PanCan-d test for their patients.

“Receiving licensure in Rhode Island now allows us to offer IMMray PanCan-d in 46 states. We expect additional state licensures to follow, as we work to make IMMray PanCan-d accessible to patients across the United States who are at risk for pancreatic cancer,” says Jeff Borcherding, Chief Executive Officer of Immunovia, Inc.

Advertisement

Photo of Jeff Borcherding

Advertisement

Related Posts

agreement
November 10, 2015

CardiNor AS, a newly established Norwegian biotech company has received an initial USD 0,75 million to start development of an IVD for the neuropeptide Secretoneurin (SN). This neuropeptide is creating a great deal of interest as the potential missing link in  assessment and management of the 30 million patients having…

June 23, 2021

AstraZeneca and HUTCHMED’s Orpathys has been granted conditional approval in China to treat patients with non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations who have progressed following prior systemic therapy or are unable to receive chemotherapy. This approval follows a priority review designation by the Center for…

Anders Rylander
August 4, 2022

The FDA has granted 510(k) clearance for the product DiviTumTKa as an aid in monitoring disease progression in previously diagnosed hormone receptor positive, metastatic postmenopausal female breast cancer patients. “We are excited to have received the formal approval from FDA for our DiviTumTKa assay, which is the first FDA cleared…

Sean Bohen
October 9, 2017

AstraZeneca has announced that the US Food and Drug Administration has granted Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). “The Breakthrough Therapy Designation acknowledges not only Tagrisso’s potential as a 1st-line standard of care…